
IGC Pharma, Inc. — Investor Relations & Filings
IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing treatments for Alzheimer's disease. The company leverages artificial intelligence (AI) in its development process. Its lead candidate, IGC-AD1, is being evaluated in a Phase 2 clinical trial for treating agitation in patients with dementia due to Alzheimer's. The company's pipeline also includes TGR-63, a pre-clinical small molecule designed to inhibit amyloid plaque aggregation. Supporting its therapeutic development is MINT-AD, an AI-powered platform for the early detection of Alzheimer's and to improve the understanding of disease progression.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - IGC Pharma, Inc. (0001326205) (Filer) | 2026-04-20 | English | |
| 8-K - IGC Pharma, Inc. (0001326205) (Filer) | 2026-03-30 | English | |
| 10-KT - IGC Pharma, Inc. (0001326205) (Filer) | 2026-03-18 | English | |
| 4 Filing | 2026-02-04 | English | |
| 4 Filing | 2026-01-20 | English | |
| 8-K - IGC PHARMA, INC. (0001326205) (Filer) | 2026-01-06 | English |
Browse filings by year
22 years- 2026 7 filings
- 2025 30 filings
- 2024 37 filings
- 2023 24 filings
- 2022 19 filings
- 2021 31 filings
- 2020 32 filings
- 2019 14 filings
- 2018 43 filings
- 2017 56 filings
- 2016 23 filings
- 2015 26 filings
- 2014 40 filings
- 2013 23 filings
- 2012 48 filings
- 2011 49 filings
- 2010 61 filings
- 2009 49 filings
- 2008 91 filings
- 2007 23 filings
- 2006 26 filings
- 2005 10 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 34693717 | 8-K - IGC Pharma, Inc. (0001326205) (Filer) | 2026-04-20 | English | ||
| 33093350 | 8-K - IGC Pharma, Inc. (0001326205) (Filer) | 2026-03-30 | English | ||
| 32979091 | 10-KT - IGC Pharma, Inc. (0001326205) (Filer) | 2026-03-18 | English | ||
| 28898684 | 4 Filing | 2026-02-04 | English | ||
| 28898699 | 4 Filing | 2026-01-20 | English | ||
| 32890161 | 8-K - IGC PHARMA, INC. (0001326205) (Filer) | 2026-01-06 | English | ||
| 11848719 | FORM 8-K | 2026-01-02 | English | ||
|
2025
8 filings
| |||||
| 11848724 | FORM 8-K | 2025-12-15 | English | ||
| 11848723 | Regulatory Filings 2025 | 2025-12-08 | English | ||
| 11848725 | FORM S-3/A | 2025-12-03 | English | ||
| 11848731 | FORM S-3 | 2025-11-14 | English | ||
| 11848732 | FORM S-8 | 2025-11-14 | English | ||
| 11848730 | FORM 10-Q | 2025-11-14 | English | ||
| 11848726 | FORM 8-K | 2025-11-14 | English | ||
| 11848727 | Director's Dealing 2025 | 2025-10-22 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NOVOGENE CO., LTD.
Global provider of genomic services, NGS solutions, and bio…
|
688315 | CN | Professional, scientific and te… |
|
Novoheart Holdings Inc.
Engineering bioartificial human heart surrogates for drug d…
|
NVH | CA | Professional, scientific and te… |
|
NOVOPROTEIN SCIENTIFIC INC.
Develops recombinant proteins and enzymes for life sciences…
|
688137 | CN | Professional, scientific and te… |
|
NOXOPHARM LIMITED
Clinical-stage developer of novel treatments for cancer and…
|
NOX | AU | Professional, scientific and te… |
|
NUFORMIX PLC
Pharmaceutical developer using cocrystal technology to repu…
|
NFX | GB | Professional, scientific and te… |
|
Nurix Therapeutics, Inc.
Clinical-stage biopharma developing protein degradation the…
|
NRIX | US | Professional, scientific and te… |
|
NYRADA INC.
Develops small molecule therapeutics for cardiovascular hea…
|
NYR | AU | Professional, scientific and te… |
|
OLIPASS CORPORATION
An R&D company developing RNA therapeutics using its propri…
|
244460 | KR | Professional, scientific and te… |
|
OmniAb, Inc.
A technology platform for therapeutic antibody discovery us…
|
OABIW | US | Professional, scientific and te… |
|
ONCIMMUNE HOLDINGS PLC
Immunodiagnostics company specializing in antibody and auto…
|
ONC | GB | Professional, scientific and te… |
IGC Pharma, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34705/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34705 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34705 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34705 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34705}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for IGC Pharma, Inc. (id: 34705)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.